Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Position Decreased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. trimmed its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 81.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,586 shares of the company's stock after selling 297,591 shares during the quarter. Balyasny Asset Management L.P. owned about 0.08% of Syndax Pharmaceuticals worth $920,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of SNDX. Bayesian Capital Management LP purchased a new position in shares of Syndax Pharmaceuticals in the fourth quarter valued at $370,000. BNP Paribas Financial Markets raised its holdings in Syndax Pharmaceuticals by 1,128.7% in the fourth quarter. BNP Paribas Financial Markets now owns 259,245 shares of the company's stock valued at $3,427,000 after acquiring an additional 238,146 shares in the last quarter. Algert Global LLC raised its holdings in Syndax Pharmaceuticals by 65.4% in the fourth quarter. Algert Global LLC now owns 785,632 shares of the company's stock valued at $10,386,000 after acquiring an additional 310,634 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Syndax Pharmaceuticals by 23.7% in the fourth quarter. Nantahala Capital Management LLC now owns 560,532 shares of the company's stock valued at $7,410,000 after acquiring an additional 107,300 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Syndax Pharmaceuticals by 7.5% in the fourth quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after acquiring an additional 55,144 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Guggenheim reaffirmed a "buy" rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Scotiabank increased their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Trading Up 1.1%

SNDX traded up $0.10 on Friday, reaching $9.05. The company had a trading volume of 2,954,265 shares, compared to its average volume of 1,725,031. The company has a fifty day moving average of $12.10 and a 200-day moving average of $14.07. The company has a market capitalization of $778.73 million, a P/E ratio of -2.49 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. The business's quarterly revenue was up 1900.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.85) EPS. Research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).